In the latest trading session,, 0.85 million Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares changed hands as the company’s beta touched 1.38. With the company’s most recent per share price at $11.12 changing hands around $1.66 or 17.55% at last look, the market valuation stands at $650.87M. DNA’s current price is a discount, trading about -51.53% off its 52-week high of $16.85. The share price had its 52-week low at $5.00, which suggests the last value was 55.04% up since then. When we look at Ginkgo Bioworks Holdings Inc’s average trading volume, we note the 10-day average is 1.62 million shares, with the 3-month average coming to 1.32 million.
Analysts gave the Ginkgo Bioworks Holdings Inc (DNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.75. If we narrow down to specifics, the data shows that 2 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended DNA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA is in green as seen in intraday trades today. With action 30.36%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -2.08%, with the 5-day performance at 30.36% in the green. However, in the 30-day time frame, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is 53.38% up. Looking at the short shares, we see there were 11.31 million shares sold at short interest cover period of 10.64 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need a downside of -71.08% from its recent market value. According to analyst projections, DNA’s forecast low is 4.35 with 12 as the target high. To hit the forecast high, the stock’s price needs a -7.91% plunge from its current level, while the stock would need to tank 60.88% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -27.97%. The 2025 estimates are for Ginkgo Bioworks Holdings Inc earnings to increase by 41.87%.
DNA Dividends
Ginkgo Bioworks Holdings Inc is expected to release its next quarterly earnings report on 2025-May-06.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.88% of Ginkgo Bioworks Holdings Inc shares while 79.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 85.28%. There are 79.41% institutions holding the Ginkgo Bioworks Holdings Inc stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 6.9686% of the shares, roughly 143.09 million DNA shares worth $47.83 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.7679% or 138.96 million shares worth $46.46 million as of 2024-06-30.
